First Time Loading...

Theseus Pharmaceuticals Inc
NASDAQ:THRX

Watchlist Manager
Theseus Pharmaceuticals Inc Logo
Theseus Pharmaceuticals Inc
NASDAQ:THRX
Watchlist
Price: 4.06 USD Market Closed
Updated: Apr 28, 2024

Profitability Summary

Theseus Pharmaceuticals Inc's profitability score is 27/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score
27/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Theseus Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-66.5m USD
Operating Income
-66.5m USD
Other Expenses
9.9m USD
Net Income
-56.6m USD

Margins Comparison
Theseus Pharmaceuticals Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Theseus Pharmaceuticals Inc
NASDAQ:THRX
177m USD N/A N/A
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
696.4B USD
30%
15%
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK
45%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
6%
3%
US
Johnson & Johnson
NYSE:JNJ
351.8B USD
29%
50%
US
Merck & Co Inc
NYSE:MRK
332.2B USD
7%
1%
UK
AstraZeneca PLC
LSE:AZN
185.8B GBP
19%
13%
CH
Novartis AG
SIX:NOVN
182.9B CHF
27%
32%
CH
Roche Holding AG
SIX:ROG
176.2B CHF
33%
20%
Country US
Market Cap 177m USD
Operating Margin N/A
Net Margin N/A
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 696.4B USD
Operating Margin
30%
Net Margin
15%
Country DK
Market Cap 4T DKK
Operating Margin
45%
Net Margin
36%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Net Margin
-4%
Country JP
Market Cap 82T JPY
Operating Margin
6%
Net Margin
3%
Country US
Market Cap 351.8B USD
Operating Margin
29%
Net Margin
50%
Country US
Market Cap 332.2B USD
Operating Margin
7%
Net Margin
1%
Country UK
Market Cap 185.8B GBP
Operating Margin
19%
Net Margin
13%
Country CH
Market Cap 182.9B CHF
Operating Margin
27%
Net Margin
32%
Country CH
Market Cap 176.2B CHF
Operating Margin
33%
Net Margin
20%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Theseus Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Theseus Pharmaceuticals Inc
NASDAQ:THRX
177m USD
-26%
-24%
-30%
-301%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
696.4B USD
49%
9%
30%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK
88%
30%
79%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY
1%
1%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
351.8B USD
56%
23%
18%
14%
US
Merck & Co Inc
NYSE:MRK
332.2B USD
1%
0%
5%
1%
UK
AstraZeneca PLC
LSE:AZN
185.8B GBP
16%
6%
13%
11%
CH
Novartis AG
SIX:NOVN
182.9B CHF
28%
14%
16%
14%
CH
Roche Holding AG
SIX:ROG
176.2B CHF
40%
13%
30%
23%
Country US
Market Cap 177m USD
ROE
-26%
ROA
-24%
ROCE
-30%
ROIC
-301%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 696.4B USD
ROE
49%
ROA
9%
ROCE
30%
ROIC
16%
Country DK
Market Cap 4T DKK
ROE
88%
ROA
30%
ROCE
79%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country JP
Market Cap 82T JPY
ROE
1%
ROA
1%
ROCE
2%
ROIC
2%
Country US
Market Cap 351.8B USD
ROE
56%
ROA
23%
ROCE
18%
ROIC
14%
Country US
Market Cap 332.2B USD
ROE
1%
ROA
0%
ROCE
5%
ROIC
1%
Country UK
Market Cap 185.8B GBP
ROE
16%
ROA
6%
ROCE
13%
ROIC
11%
Country CH
Market Cap 182.9B CHF
ROE
28%
ROA
14%
ROCE
16%
ROIC
14%
Country CH
Market Cap 176.2B CHF
ROE
40%
ROA
13%
ROCE
30%
ROIC
23%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More